# Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

> **NCT01896050** · — · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 115 (actual)

## Conditions studied

- Breast Cancer
- Arthralgia
- Obesity

## Interventions

- **DRUG:** anastrozole, letrozole, exemestane
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT01896050
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2016-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896050, "Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01896050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*